Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be launch-ready by the end of the year if approved. Compass recently held a ...
InvestorsHub on MSN
Compass Pathways gains after FDA clears IND for PTSD trial of COMP360
Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...
The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...
BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX) announced Tuesday that key survival analyses for its lead drug tovecimig in biliary tract cancer remain on track for late Q1 2026, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback